证券代码：301230 证券简称：泓博医药 公告编号：2024-073 上海泓博智源医药股份有限公司 独立董事关于公开征集表决权的公告 独立董事程立保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别声明 1. 本次征集表决权为依法公开征集，征集人程立符合《中华人民共和国证券法》 第九十条、《上市公司股东大会规则》第三十一条、《公开征集上市公司股东权利管 理暂行规定》第三条规定的征集条件； 2. 截至本公告披露日，征集人程立未直接或间接持有上海泓博智源医药股份有限 公司股份。 按照中国证券监督管理委员会（以下简称"中国证监会"）《上市公司股权激励 管理办法》（以下简称"《管理办法》"）等法律、法规及规范性文件的有关规定， 并根据上海泓博智源医药股份有限公司（以下简称"公司"）其他独立董事的委托， 独立董事程立作为征集人就公司拟于 2024 年 11 月 18 日召开的 2024 年第三次临时股 东大会中审议的 2024 年限制性股票激励计划（以下简称"本次激励计划"）相关议案 向公司全体股东征集表决权。 中 ...

2、本激励计划拟首次授予的激励对象不包括公司董事（含独立董事）、监事，也不包括单独或合计持 有公司 5%以上股份的股东或实际控制人及其配偶、父母、子女。 3、预留部分的激励对象由本激励计划经股东大会审议通过后 12 个月内确定，经董事会提出、监事会 发表明确意见、律师发表专业意见并出具法律意见书后，公司在指定网站按要求及时准确披露当次激励对 象相关信息。 上海泓博智源医药股份有限公司 2024 年限制性股票激励计划首次授予激励对象名单 一、公司 2024 年限制性股票激励计划（以下简称"本激励计划"）的分配 | 情况 | | --- | | 序 | | | | 获授的限制 | 占授予限制 | 占本激励 计划草案 | | --- | --- | --- | --- | --- | --- | --- | | 号 | 姓名 | 国籍 | 职务 | 性股票数量 | 性股票总量 | 公告日公 | | | | | | （万股） | 的比例 | 司股本总 | | | | | | | | 额的比例 | | 1 | ZHEN-WEI | 美国 | 副总经理 | 6.00 | 4.88% | 0.04% | | | CAI | ...

证券代码：301230 证券简称：泓博医药 公告编号：2024-071 上海泓博智源医药股份有限公司 第三届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 1、审议通过《关于<上海泓博智源医药股份有限公司 2024 年限制性股票激励计划 （草案）>及其摘要的议案》 经审核，监事会认为《上海泓博智源医药股份有限公司 2024 年限制性股票激励计 划（草案）》及其摘要的内容符合《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股权激励管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交 易所创业板上市公司自律监管指南第 1 号——业务办理》等有关法律、法规和规范性 文件以及《公司章程》的规定，履行了相关的法定程序，有利于公司的长远发展，不 存在明显损害公司及全体股东利益的情形。 表决结果：5 票同意，0 票反对，0 票弃权。 本议案需提交股东大会审议，且须经出席本次股东大会的股东所持有的表决权数 1 一、监事会会议召开情况 上海泓博智源医药股份有限公司（以下简称"公司"）于 2024 年 10 月 30 日向公司 全体监 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown steady revenue growth in the first three quarters, with a year-on-year increase of 6.59% to 391 million yuan, but the profit has been under pressure, with a significant decline in net profit by 66.81% year-on-year to 15.24 million yuan [4] - The decline in profit is attributed to the decrease in gross margins in the CDMO and commercialization segments, leading to fluctuations in profit [4] - The company has adjusted its profit forecasts for 2024-2026, expecting net profits of 21 million yuan, 38 million yuan, and 65 million yuan respectively, with corresponding EPS of 0.15, 0.27, and 0.47 yuan [4] Summary by Sections Revenue and Profit Performance - In Q3 2024, the company reported revenue of 126 million yuan, a decrease of 3.02% year-on-year and 6.96% quarter-on-quarter, with a net profit of -730,000 yuan [4] - The overall revenue for the first three quarters was stable, but the profit was significantly impacted by the decline in gross margins from key segments [4] Business Segments - The drug discovery business achieved revenue of 158 million yuan in H1 2024, a year-on-year increase of 14.75% [5] - The service segment saw a rapid increase in new orders, with Q2 new orders reaching 165 million yuan, a quarter-on-quarter growth of 42.42% [5] - The commercialization production segment reported revenue of 79.2 million yuan in H1 2024, a year-on-year increase of 72.31% [6] Financial Forecasts - The company has revised its earnings forecasts downward for 2024-2026, with expected net profits of 21 million yuan, 38 million yuan, and 65 million yuan, and corresponding EPS of 0.15, 0.27, and 0.47 yuan [4] - The projected P/E ratios for the next three years are 169.2, 93.8, and 54.8 times respectively [4] Market Position and Strategy - The company is expected to benefit from the recovery in overseas demand, with new orders showing steady growth [4] - The CADD/AIDD technology platform has supported 69 new drug projects, with ongoing progress in the PR-GPT project expected to enter commercial operation in Q4 2024 [5]

公 司 研 究 | --- | --- | --- | |-------|-----------|-------| | | | | | | | | | | | | | | | | | 日 | 27 | | | | 公司点评 | | | | 买入/维持 | | 泓博医药(301230) 目标价: 昨收盘:25.88 Q3 收入略有波动，短期利润有所承压 ◼ 走势比较 (40%) (26%) (12%) 2% 16% 30% 23/10/2724/1/724/3/1924/5/3024/8/1024/10/21 泓博医药 沪深300 ◼ 股票数据 总股本/流通(亿股) 1.4/0.77 总市值/流通(亿元) 36.13/19.89 12 个月内最高/最低价 (元) 54.99/18.41 相关研究报告 <<收入实现稳定增长，订单环比改善 明显>>--2024-08-28 <>-- 2023-10-27 <<小分子药物设计专家，一站式赋能 新药研发>>--2023-09-27 事件： 10 月 27 日，公司发布 2024 年三季报，2024 年前三季度实现营业收 入 3.91 亿元，同比增长 6.59%，归母净利 ...

证券代码：301230 证券简称：泓博医药 公告编号：2024-069 上海泓博智源医药股份有限公司 关于部分募投项目结项并将节余募集资金 永久补充流动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 上海泓博智源医药股份有限公司（以下简称"公司"）于 2024 年 10 月 24 日召开 第三届董事会第十九次会议及第三届监事会第十三次会议，审议通过《关于部分募投项 目结项并将节余募集资金永久补充流动资金的议案》，同意公司将"临床前新药研发基 地建设项目（二期）"结项，并将截至 2024 年 9 月 30 日的节余募集资金共计 496.54 万元（含铺底流动资金及活期利息收入，具体金额以资金转出当日银行结算余额为准） 永久补充流动资金，用于子公司上海泓博尚奕药物技术有限公司日常经营活动。上述节 余募集资金划转完成后，公司将注销相关募集资金专项账户，募投项目尚需支付的部分 合同尾款和质保金将全部由自有资金支付。专户注销后，公司与子公司、保荐机构、存 放募集资金的银行签署的相关《募集资金四方监管协议》随之终止。 根据深圳证券交易所《深圳证券交易所创业板股 ...

第三届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：301230 证券简称：泓博医药 公告编号：2024-068 上海泓博智源医药股份有限公司 一、监事会会议召开情况 上海泓博智源医药股份有限公司（以下简称"公司"）第三届监事会第十三次会议 通知于 2024 年 10 月 18 日以邮件形式送达全体监事。会议于 2024 年 10 月 24 日上午 10:30 在上海市浦东新区凯庆路 59 号 12 幢二楼公司会议室以现场结合通讯表决的方式 召开。本次会议由监事会主席刘国东先生主持召开，应出席监事 5 名，实际出席 5 名。 会议召开及表决程序符合《中华人民共和国公司法》及《上海泓博智源医药股份有限 公司章程》（以下简称"《公司章程》"）的有关规定。 二、监事会会议审议情况 经出席会议的全体监事认真审议，通过了如下议案： 1、审议通过《关于<2024 年第三季度报告>的议案》 经审核，监事会认为：公司《2024 年第三季度报告》编制和审核程序符合法律、 行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了公司 2 ...

证券代码：301230 证券简称：泓博医药 公告编号：2024-067 上海泓博智源医药股份有限公司 经与会董事审议，公司 2024 年第三季度报告的编制和审核程序符合法律、行政法 规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在 任何虚假记载、误导性陈述或者重大遗漏。 本议案经公司审计委员会审议通过。 本议案无需提交股东大会审议。 表决结果：同意 7 票，反对 0 票，弃权 0 票。 第三届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海泓博智源医药股份有限公司（以下简称"公司"）第三届董事会第十九次会议 通知于 2024 年 10 月 18 日以邮件的形式送达全体董事。会议于 2024 年 10 月 24 日上午 10:00 在上海市浦东新区凯庆路 59 号 12 幢二楼公司会议室以现场结合通讯表决的方式 召开。会议应出席董事 7 名，实际出席 7 名。本次会议由董事长 Ping Chen 博士主持召 开，公司监事、高级管理人员列席了会议。会议召开及表决程序符合《中华人民共 ...

中信证券股份有限公司 关于上海泓博智源医药股份有限公司 部分募投项目结项并将节余募集资金永久补充流动资金的 核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为上海泓博智 源医药股份有限公司（以下简称"泓博医药"或"公司"）首次公开发行股票并在深 圳证券交易所创业板上市的保荐人，根据《证券发行上市保荐业务管理办法》《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深 圳证券交易所创业板股票上市规则》等相关规定，对公司此次部分募投项目结项 并将节余募集资金永久补充流动资金的事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意上海泓博智源医药股份有限公司首次 公开发行股票注册的批复》（证监许可〔2022〕1443 号）同意注册，公司向社会 公开发行人民币普通股 1,925 万股，共计募集资金人民币 77,000.00 万元，扣除 发行相关费用合计人民币 8,415.16 万元，实际募集资金净额为人民币 68,584.84 万元。上述募集资金到位情况业经立信会计师 ...

Revenue and Profit Performance - Revenue for the third quarter was RMB 125.64 million, a decrease of 3.02% year-over-year[4] - Net profit attributable to shareholders was RMB -732,885.31, a significant decrease of 105.62% year-over-year[4] - Net profit attributable to the parent company decreased to 166.4 million yuan from 186.3 million yuan, a decline of 10.7%[14] - Net profit for the quarter was RMB 15.24 million, with a year-to-date net profit of RMB 45.93 million[16] - Total revenue for the period reached 391.4 million yuan, compared to 367.2 million yuan in the same period last year, representing a 6.6% increase[15] - Sales revenue from goods and services for the quarter was RMB 341.35 million, slightly down from RMB 352.72 million in the same period last year[17] Cash Flow and Financial Position - Operating cash flow for the first nine months was RMB 21.11 million, down 59.97% year-over-year[4] - Operating cash flow for the quarter was RMB 21.11 million, compared to RMB 52.72 million in the same period last year[17] - Investment cash flow improved by 83.63% to RMB -6.94 million, reflecting reduced payments for clinical new drug R&D projects[7] - Investment cash inflow for the quarter was RMB 597.25 million, a decrease from RMB 1 billion in the same period last year[17] - Total cash outflow from financing activities was RMB 130.64 million, with a net cash outflow of RMB 110.99 million[18] - Total cash outflow from investment activities was RMB 590.15 million, compared to RMB 1.66 billion in the same period last year[17] - The company's cash and cash equivalents decreased by RMB 79.99 million during the quarter[18] - Cash and cash equivalents at the end of the quarter were RMB 55.50 million, down from RMB 106.33 million at the end of the previous quarter[18] - Net cash flow from financing activities was -31,198,413.09, a decrease of 340.56% compared to the previous period, mainly due to cash dividends, share repurchases, and clinical new drug R&D expenses[8] Assets and Liabilities - Total assets decreased by 8.67% to RMB 1.36 billion compared to the end of the previous year[4] - Total assets decreased to 1.36 billion yuan from 1.49 billion yuan, a reduction of 8.8%[13] - Current assets declined to 620.5 million yuan from 731.3 million yuan, a 15.1% decrease[12] - Accounts receivable increased to 109.7 million yuan, up 28.3% from 85.5 million yuan in the previous period[12] - Inventory rose to 77.5 million yuan, a 26.1% increase compared to 61.4 million yuan in the prior year[12] - Short-term borrowings decreased to 12.3 million yuan from 15.9 million yuan, a 22.6% reduction[13] - Total liabilities decreased to 313.6 million yuan from 369.6 million yuan, a 15.1% decline[13] - Contract liabilities increased by 131.91% to RMB 5.15 million due to pre-receipts for uncompleted orders[7] - Deferred tax assets grew by 142.62% to RMB 24.97 million, driven by losses from clinical new drug R&D projects[7] R&D and Operating Costs - R&D expenses increased by 38.66% to RMB 13.08 million in the third quarter[7] - R&D expenses grew to 35.9 million yuan, a 25% increase compared to 28.7 million yuan in the prior year[15] - Operating costs increased to 396.6 million yuan, up from 319.4 million yuan in the previous year, reflecting a 24.2% rise[15] - Operating profit dropped by 131.95% to RMB -4.06 million, mainly due to incomplete capacity release in clinical new drug R&D projects[7] Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period was 12,390[8] - The largest shareholder, Hongbo Zhiyuan (Hong Kong) Pharmaceutical Technology Co., Ltd., holds 27.71% of the shares, totaling 38,675,000 shares[8] - Shenyang Fubang Investment Co., Ltd. holds 6.21% of the shares, totaling 8,663,200 shares[8] - Dingtai Haifu Investment Management Co., Ltd. holds 4.94% of the shares, totaling 6,901,230 shares[8] - Beijing Zhongfu Jishi Investment Center (Limited Partnership) holds 4.42% of the shares, totaling 6,164,860 shares[8] - Shanghai Dingyun Investment Management Consulting Partnership (Limited Partnership) holds 3.89% of the shares, totaling 5,423,600 shares[8] - Beijing Zhongfu Growth Equity Investment Center (Limited Partnership) holds 2.01% of the shares, totaling 2,802,800 shares[8] - The total number of restricted shares at the end of the period was 62,726,300, an increase of 14,475,300 shares compared to the beginning of the period[10] Earnings and Comprehensive Income - Basic earnings per share for the quarter were RMB 0.1099, with year-to-date basic earnings per share at RMB 0.4268[16] - Total comprehensive income for the quarter was RMB 15.24 million, with year-to-date comprehensive income at RMB 46.00 million[16] Financial Expenses - Financial expenses surged by 4409.66% to RMB 2.21 million due to unconfirmed financing fees for right-of-use assets[7]